Second generation BTK inhibitors impair the anti‐fungal response of macrophages and neutrophils

Ibrutinib induces multiple functional defects in the neutrophil response against Aspergillus fumigatus

(2019) Damien Blez et al.   HAEMATOLOGICA

Ibrutinib blocks Btk-dependent NF-ĸB and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis

(2018) Amelia Bercusson et al.   BLOOD

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

(2018) Anthony R. Mato et al.   HAEMATOLOGICA

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

(2018) Anthony R. Mato et al.   HAEMATOLOGICA

Effect of the BTK inhibitor ibrutinib on macrophage- and γδ T cell-mediated response against Mycobacterium tuberculosis

(2018) Ana Colado et al.   Blood Cancer Journal

The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies

(2017) Josée Golay et al.   HAEMATOLOGICA

Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile

(2017) Tjeerd Barf et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies

(2017) Josée Golay et al.   HAEMATOLOGICA

Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia

(2016) Stefania Fiorcari et al.   Oncotarget